Theravance gains on Breo briefing docs

Theravance Inc. (NASDAQ:THRX) gained $4.60 (19%) to $28.36 on Monday after FDA reviewers did not raise any new safety concerns for Breo fluticasone furoate/vilanterol from Theravance and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). FDA reviewers also said Breo's safety profile is similar to other combination products approved for chronic obstructive pulmonary disease (COPD) in adrenergic receptor beta 2 agonist (LABA). ...